These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 38394074)

  • 1. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
    Gimenez-Arnau AM; Salman A; Podder I
    Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Spontaneous Urticaria: An Update on the Evaluation and Management.
    Joshi SR; Anstey KM; Khan DA
    Immunol Allergy Clin North Am; 2024 Aug; 44(3):503-515. PubMed ID: 38937012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Antihistamines During Omalizumab Therapy in Chronic Urticaria in the Routine Clinical Practice. A 48-Patient Observational Trial.
    Menéndez-Sánchez M; Pérez-Fernández E; López-Estebaranz JL; Gómez-de la Fuente E
    Actas Dermosifiliogr; 2024 Jun; 115(6):636-638. PubMed ID: 38382744
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria.
    Kaur S; Jabbal IS; Bhasin AK
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35850790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities.
    Staubach P; Bilo B; Fluhr JW; Krause K; Kulthanan K; Salman A; Katelaris C; Bernstein JA; Maurer M; Mann C
    J Dermatolog Treat; 2024 Dec; 35(1):2329784. PubMed ID: 38508226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A protocol for the development and internal validation of a model to predict clinical response to antihistamines in urticaria patients.
    Sanchez J; Velasquez M; Jaimes F
    PLoS One; 2020; 15(10):e0239962. PubMed ID: 33022026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the use of antihistamines in managing chronic urticaria.
    Xiang YK; Fok JS; Podder I; Yücel MB; Özkoca D; Thomsen SF; Kocatürk E
    Expert Opin Pharmacother; 2024 Apr; 25(5):551-569. PubMed ID: 38654448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatographism With Genital Symptoms Treated With Antihistamines: A Case Series.
    Cunningham KN; Rivera S; Holmes Seward S; Mirowski GW
    J Cutan Med Surg; 2024; 28(3):291-292. PubMed ID: 38519833
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparing four immunosuppressive agents for chronic spontaneous urticaria-A network meta-analysis.
    Bei W; Qian J; Zilu Q; Kai C; Ruili J; Feng H; Liuqing C
    Int Immunopharmacol; 2023 Oct; 123():110577. PubMed ID: 37567010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk calculator of the clinical response to antihistamines in chronic urticaria: Development and internal validation.
    Sánchez J; Jaimes F; García E; Zakzuk J; Cardona R; Velasquez M
    PLoS One; 2024; 19(2):e0295791. PubMed ID: 38394074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
    Abe N; Bohgaki M; Kasahara H
    Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
    Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
    J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.